Freely Filtered 057: NephMadness 2023 TMA
Freely Filtered, a NephJC Podcast
Do You Think We Should Talk About the Alternative Compromised Pathway?
On the poster tour that we did at Kidney Week, we went and we saw some, I think it was data from the Netherlands about stopping eculizumab and these patients. They actually were pretty successful. If you have a genetic mutation, those patients need to stay on their meds. So that's the, so it's feasible. I think it's doable, but you really have to pick your patients.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
